These positive results will be presented on
Alfact Innovation has developed ALF-5755, a recombinant protein of the human protein HIP/PAP with in vivo therapeutic effect on a fas model of Acute Liver Failure. ALF-5755 was tested in 57 patients in a double blind controlled trial in European medical centers coordinated by Professor
“Acute Liver Failure develops in a matter of days and requires immediate hospitalization. While some patients can undergo medical treatment, the majority need a high-risk liver transplant. ALF-5755 is a new milestone in the ongoing struggle against this pathology. The phase II clinical trial demonstrated the efficacy of this novel antioxidant in patients with HBV- and autoimmune- related acute on chronic liver diseases. This brings tremendous hope to clinicians and patients alike and represents a major step forward in the treatment of ALF,” commented Professor
Acute Liver Failure – ALF – is a rare condition in which the liver rapidly loses its ability to function, resulting in coagulopathy and alteration in the mental status of a previously healthy individual. Despite the improvement in overall survival in the last 20 years due to emergency interventions, ALF remains a life-threatening disease with about 30% of mortality rate. Hence, ALF remains a high unmet medical need.
For more information, please visit: http://www.alfactinnovation.com/
Source: Alfact Innovation